[{"address1": "Building 8", "address2": "No. 8 Life Science Park Road Zhongguancun Life Science Park Changping District", "city": "Beijing", "zip": "102206", "country": "China", "phone": "86 10 6660 9999", "fax": "86 10 6070 2992", "website": "https://www.innocarepharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical development collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.", "fullTimeEmployees": 1089, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jisong  Cui Ph.D.", "age": 59, "title": "Co-Founder, Chairwoman & CEO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 1033730, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Renbin  Zhao Ph.D.", "age": 54, "title": "VP of Regulatory Affairs & Clinical Development and Executive Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 401231, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Xin  Fu", "title": "Chief Financial Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nan  Gao", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiangyang  Chen Ph.D.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Junsu  Wang", "age": 46, "title": "General Counsel", "yearBorn": 1977, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiang-Yang  Zhang M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Davy  Ouyang Ph.D.", "title": "VP & Head of Biology", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Chen", "title": "Chief Commercial Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pui Shan  Lee", "title": "Company Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.26, "open": 3.26, "dayLow": 3.26, "dayHigh": 3.26, "regularMarketPreviousClose": 3.26, "regularMarketOpen": 3.26, "regularMarketDayLow": 3.26, "regularMarketDayHigh": 3.26, "beta": 1.115, "volume": 900, "regularMarketVolume": 900, "bid": 0.6269, "ask": 0.707, "marketCap": 4877873152, "fiftyTwoWeekLow": 3.26, "fiftyTwoWeekHigh": 3.26, "priceToSalesTrailing12Months": 6.6047783, "fiftyDayAverage": 3.26, "twoHundredDayAverage": 3.26, "currency": "USD", "enterpriseValue": -851586688, "profitMargins": -0.85475, "floatShares": 934459140, "sharesOutstanding": 1496280064, "heldPercentInsiders": 0.30493, "heldPercentInstitutions": 0.36022, "bookValue": 4.054, "priceToBook": 0.8041441, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -631262912, "trailingEps": -0.03, "enterpriseToRevenue": -1.153, "enterpriseToEbitda": 1.31, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "INCPF", "underlyingSymbol": "INCPF", "shortName": "INNOCARE PHARMA LTD", "longName": "InnoCare Pharma Limited", "firstTradeDateEpochUtc": 1625837400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d8031191-20d4-3024-a929-54050da27832", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.26, "recommendationKey": "none", "totalCash": 8287136768, "totalCashPerShare": 4.7, "ebitda": -650149696, "totalDebt": 1654887680, "quickRatio": 4.128, "currentRatio": 4.21, "totalRevenue": 738537024, "debtToEquity": 23.046, "revenuePerShare": 0.433, "returnOnAssets": -0.043709997, "returnOnEquity": -0.0871, "freeCashflow": -837218432, "operatingCashflow": -665489536, "revenueGrowth": 0.095, "grossMargins": 0.8261, "ebitdaMargins": -0.88031995, "operatingMargins": -0.95926005, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]